Objective
to report the 3-year clinical outcomes of transcatheter aortic valve implantation with Accurate Neo (self-expanding) compared to Edwards Sapien 3 (balloon-expanding)
Study
multicentre, investigator-initiated randomised trial
Population
elderly patients with symptomatic severe aortic stenosis
Endpoints
composite of all-cause death, any stroke or hospitalisation for heart failure at 3 years


Conclusion
the 3-year adverse event rate of transcatheter implantation for severe aortic stenosis with Accurate Neo was not statistically different from Edwards Sapien implantation
Lanz et al. Circulation Cardiovasc Interv. 2023: 16: e012873